key: cord-0738815-3tiefu81
authors: Pechlivanidou, Evmorfia; Vlachakis, Dimitrios; Tsarouhas, Konstantinos; Panidis, Dimitris; Tsitsimpikou, Christina; Darviri, Christina; Kouretas, Dimitrios; Bacopoulou, Flora
title: The prognostic role of micronutrient status and supplements in COVID-19 outcomes: A systematic review
date: 2022-02-25
journal: Food Chem Toxicol
DOI: 10.1016/j.fct.2022.112901
sha: 438f323082c47092cd47fed6cc170fa639b20367
doc_id: 738815
cord_uid: 3tiefu81

Micronutrients constitute an adjuvant treatment for respiratory viral infections. Since there is no effective antiviral therapy for COVID-19 yet, adjuvant intervention for the survival of critically ill patients may be significant. Search of the PubMed, CINAHL and Cochrane databases was carried out to find human studies investigating the prognostic role of micronutrient status and the effects of micronutrient supplementation intervention in COVID-19 outcomes of adult patients. Patients with certain comorbidities (diabetes mellitus type 2, obesity, renal failure, liver dysfunction etc.) or pregnant women were excluded. 31 studies (27 observational studies and 4 clinical trials) spanning the years 2020–2021, pertaining to 8624 COVID-19 patients (mean age±SD, 61 ± 9 years) were included in this systematic review. Few studies provided direct evidence on the association of serum levels of vitamin D, calcium, zinc, magnesium, phosphorus and selenium to patients' survival or death. Vitamin D and calcium were the most studied micronutrients and those with a probable promising favorable impact on patients. This review highlights the importance of a balanced nutritional status for a favorable outcome in COVID-19. Micronutrients’ deficiency on admission to hospital seems to be related to a high risk for ICU admission, intubation and even death. Nevertheless, evidence for intervention remains unclear.

In December 2019, the Municipal Health Commission of Wuhan identified a large number of cases of viral pneumonia of unknown etiology. Soon, through sequence analysis, a new virus of the coronavirus family was identified and named SARS-CoV-2, while the resulting disease was named Corona Virus Induced Disease 2019 (COVID-19) . By February 2020 the widespread transmission of the virus outside China became apparent, while on March 12, 2020, the World Health Organization (WHO) characterized the situation as a pandemic (WHO, 2020a) . In early February 2021 the cases had exceeded 100 million worldwide, while over 2 million people had lost their lives due to COVID-19 (WHO, 2020b) .

While SARS-CoV-2 seems to be accompanied by lower mortality rates than the previous corona viruses MERS and SARS-CoV-1, it is more contagious . Current estimates of mortality rates range from 0.5 to 3.5% overall (compared to 0.1% for seasonal flu) and are significantly higher in the elderly, people with comorbidities, or the immunosuppressed. Key risk factors are age over 65 years, coronary heart disease, heart failure, diabetes mellitus, chronic obstructive pulmonary disease, obesity and smoking (Guo et al., 2020; Huang et al., 2020a; Wang et al., 2020) .

Vaccination has been proven a safe and efficient strategy against SARS-CoV-2 spread, the rapidity of which has substantially reduced the number of new COVID-19 cases and their severity in highly vaccinated countries, while microRNAs have been introduced as promising antiviral agents aside from their crucial use in vaccine technology .

However, antiviral treatment and evidence of other favorable interventions need further development (Tavilani et al., 2021; Whittaker et al., 2021) . Regarding prognosis, risk factors have been clarified but recovery predictors are still under research (Abrahim et al., 2020; Alvarez-Esteban et al., 2021; Ny et al., 2021; Rydwik et al., 2021; Tolossa et al., 2021) .

Recent reviews agree that micronutrients play a crucial role in COVID-19 progression, prognosis and survival, as in multiple other viral infections that primarily affect the respiratory track (Cheng, 2020; Grant et al., 2020; Rozga et al., 2021; Zhang and Liu, 2020) .

The well-known essential role of vitamins, minerals, metalloids and other micronutrients in J o u r n a l P r e -p r o o f many biological, biochemical and molecular processes along with in vivo studies demonstrating a significant role of several micronutrients in COVID-19, led clinicians use micronutrients as a promising adjuvant therapy against SARS-CoV-2 severe pneumonia (Domingo and Marquès, 2021; Thakur et al., 2021) . The already studied nutritional interventions for SARS-CoV and MERS-CoV infections and the underlying mechanism via which micronutrients inhibit these viruses are encouraging, as SARS-CoV-2 shares a 79.5% sequence identity with SARS-CoV and 50% with MERS-CoV (Jin et al., 2020; Jin et al., 2020; . Especially zinc and flavonoids have been proven to inhibit a special protease of the virus called 3C and improve survival (Jo et al., 2019; Jo et al.,2020; Keil et al., 2016; Lin et al., 2017; Ryu et al., 2010) .

This systematic review summarizes and describes human studies investigating the prognostic role of micronutrient status and the effects of micronutrient supplementation intervention in COVID-19 outcomes of adult patients.

The present systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic and comprehensive search of the PubMed, CINAHL and Cochrane databases was carried out for papers published from database inception until 27 April 2021. We used the following search algorithm: ("Wuhan coronavirus" or "Wuhan virus" or "novel coronavirus" or "nCoV" or "SARS-CoV-2" or "SARS 2" or "severe acute respiratory syndrome coronavirus 2" or "COVID-19" or "coronavirus disease 2019 virus" or "2019-nCoV" or "2019 novel coronavirus" or "severe acute respiratory syndrome coronavirus 2" or "coronavirus" or "coronaviruses") AND ("Vitamin D" or "vitamin D" or "25-OH-calciferol" or "25 hydroxy calciferol " or "25-OH-vit D" or "25-OH-vitamin d" or "25 hydroxy vitamin d" or Mg or zinc or "vitamin C" or "ascorbate" or "ascorbic acid" or Ca or antioxidants or micronutrients) J o u r n a l P r e -p r o o f AND patients AND prognosis. The references of all eligible articles were also checked thoroughly.

The eligibility criteria were based on the PICOS (Participants, Intervention, Comparison, Outcomes, Study design) acronym. Studies of COVID-19 inpatients, outpatients or both were included in the review, if they fulfilled the following criteria: (i) written in English language;

(ii) investigated outcomes among SARS-CoV-2 infected adults according to specific micronutrients' blood levels; (iii) were prospective or retrospective cohort studies or crosssectional studies or clinical trials; (iv) the study presented its final results; (v) there was a precise determination of the patients' levels of the studied micronutrient at the beginning and/or during the study protocol, so that objective evidence of the sufficiency or insufficiency of the studied micronutrient could be provided. Regarding the determination of prognosis, all studies looking for outcomes such as severe disease, need for mechanical ventilation (MV), intensive care unit (ICU) admission, mortality, end or duration of hospitalization, reduction of blood inflammatory markers and those estimating certain survival scores were included, to enclose only studies with specific or measurable outcomes. Studies were excluded if they focused only on patients with certain comorbidities (such as diabetes mellitus type 2, obesity, renal failure, liver dysfunction etc.) or pregnant women. These populations were excluded because their pre-comorbid conditions might had precluded potentially beneficial effects of vitamin supplements, whereas pregnant women might had already been taking nutrient supplements to maintain adequate micronutrient levels throughout gestation. Studies evaluating prognosis only throughout the improvement of symptoms were also excluded.

Titles and abstracts of studies were retrieved using the search strategy for all three databases and were extracted independently by three different authors (EP, DV and FB). These authors (EP, DV and FB) screened for eligibility the titles and abstracts of the retrieved papers and analyzed the full-text articles that met the eligibility criteria. Data extraction was performed J o u r n a l P r e -p r o o f as following: first author and year of publication, studied micronutrient, country, study design, demographic information (age, sex), sample size, COVID-19 test type for diagnosis, time of micronutrients laboratory evaluation, criteria for prognosis evaluation, results.

Automation tools were not used in this process.

This article is a review of previously conducted studies, in accordance with the PRISMA guidelines. (Vit E), melatonin, N-acetylcysteine and pentoxifylline were also studied.

This systematic review included 8,624 COVID-19 patients with a mean age of 54 years.

Among them 527 participated in clinical trials. Three studies (2 observational and 1 clinical trial) included COVID-19 patients who had been admitted to the ICU since their first hospitalization day (Chavarria et al., 2021; Vassiliou et al., 2020; Zheng et al., 2021) .

As outcomes indicating prognosis most studies (21/31) used mortality or survival as primary or secondary outcomes (Alamdari et al., 2020; Bennouar et al., 2021; Capone et al., 2020; Carpagnano et al., 2021; Doaei et al., 2021; Entrenas Castillo et al., 2020; Ersoz and Yilmaz, 2021; Heller et al., 2021; Infante et al., 2021; Karahan and Katkat, 2021; Kashefizadeh et al., 2020; Lohia et al., 2021; Meisel et al., 2021; Moghaddam et al., 2020; Murai et al., 2021; Radujkovic et al., 2020; Sun et al., 2020; Tehrani et al., 2021; Tezcan et al., 2020; Vassiliou et al., 2020; Zheng et al., 2021) . ICU admission or need for such admission was studied in 9/31 studies (Capone et al., 2020; Entrenas Castillo et al., 2020; Ersoz and Yilmaz, 2021; Lagier et al., 2020; Liu et al., 2020; Maghbooli et al., 2020; Murai et al., 2021; Tezcan et al., 2020; Yang et al., 2021) , 9/31 studies used "length of hospitalization" (Capone et al., 2020;  J o u r n a l P r e -p r o o f Entrenas Castillo et al., 2020; Ersoz and Yilmaz, 2021; Lagier et al., 2020; Liu et al., 2020; Maghbooli et al., 2020; Murai et al., 2021; Tezcan et al., 2020; Yang et al., 2021) , MV was used by 5/31 Murai et al., 2021; Radujkovic et al., 2020; Sun et al., 2020; Tezcan et al., 2020) , blood levels of inflammatory markers were used by 8/31 (Carpagnano et al., 2021; Chavarria et al., 2021; Karahan and Katkat, 2021; Liu et al., 2020; Maghbooli et al., 2020; Radujkovic et al., 2020; Ricci et al., 2021; Yang et al., 2021) The main characteristics and results of the studies are presented in Tables 1 and 2, respectively. 

Most studies in this systematic review focused on prognostic role of Vit D in COVID-19.

given that in 5 studies survivors revealed higher levels on admission than non-survivors, while in 2 studies Vit D deficiency was related to higher mortality risk ratio (Bennouar et al., 2021; Carpagnano et al., 2021; Infante et al., 2021; Karahan and Katkat, 2021; Kashefizadeh et al., 2020; Radujkovic et al., 2020; Ricci et al., 2021; Tehrani et al., 2021; Vassiliou et al., 2020) . MV was more common among patients with Vit D deficiency than patients with normal Vit D levels in a single study (Radujkovic et al., 2020) . Inflammatory markers on admission were higher among patients with low Vit D levels than the rest or an inverse association between Vit D levels and inflammatory markers was detected (Carpagnano et al., 2021; Karahan and Katkat, 2021; Maghbooli et al., 2020; Radujkovic et al., 2020; Ricci et al., 2021) . Finally, 4/14 studies concluded that Vit D was not associated to prognosis of COVID-19 patients (Allard et al., 2020; Ersoz and Yilmaz, 2021; Lohia et al., 2021; Murai et al., 2021) , whereas one clinical trial targeting Vit D levels, reported significantly lower risk for ICU admission of the intervention group vs. controls, with only 1 patient receiving Vit D supplementation admitted to ICU (Entrenas Castillo et al., 2020) .

Ca levels constituted a prognostic factor for COVID-19 patients. Survival was associated with normocalcemia and higher Ca levels (within normal limits) were related to higher survival rates (Bennouar et al., 2021; Kashefizadeh et al., 2020; Sun et al., 2020; Zheng et al., 2021) . Low Ca levels were also a prognostic marker for the development of severe disease (Yang et al., 2021; Zhao et al., 2021) . Duration of hospitalization and ICU admission were related to low admission Ca blood levels in some cases Yang et al., 2021) whereas in 3 studies Ca was not a useful biomarker for prognosis (Alamdari et al., 2020; Allard et al., 2020; Tezcan et al., 2020) .

Low Zn blood levels were associated with the development of severe disease, more complications or longer hospitalization (Allard et al., 2020; Jothimani et al., 2020; Lagier et al., 2020) . In some cases, survival was associated with high admission Zn levels (Heller et al., 2021; Lagier et al., 2020) but this was not verified in all studies (Capone et al., 2020) .

Survival was associated with high blood levels of Se (Heller et al., 2021; Moghaddam et al., 2020) , Mg (Alamdari et al., 2020; Kashefizadeh et al., 2020) , P (Yang et al., 2021) . Similarly, severe disease was inversely associated to P and Mg levels (Allard et al., 2020) .

Several clinical trials suggested that micronutrients' supplementation was helpful in clinical improvement and survival of COVID-19 patients (Chavarria et al., 2021; Doaei et al., 2021; Entrenas Castillo et al., 2020; Murai et al., 2021) .

This review examines whether micronutrient status of COVID-19 patients is related to the course and outcome of the disease but even a year after the characterization of COVID-19 as a pandemic, direct evidence is still weak. Previous experience on the treatment of other SARS and viral infections suggests that nutrition may alter the outcome even in critically ill J o u r n a l P r e -p r o o f patients (Rowe et al., 2021) . In addition, the activation of inflammation and development of an effective immune system are primarily associated to nutrition utilization (Marcos et al., 2003) . The importance of inflammation in COVID-19 prognosis has been highlighted in survival analysis, as neutrophil-to-lymphocyte ratio and white blood cells have been introduced as one-month mortality predictors in COVID-19 (Vafadar Moradi et al., 2021) .

Nutrient deficiency alters cells regeneration and function, suppresses immune response, and contributes to diabetes mellitus type II, hypertension and coronary heart disease in the elderly (Bjorklund et al., 2020; Farrokhian et al., 2016; Holmberg et al., 2017; Langley-Evans and Carrington, 2006) .

COVID-19 has a multiplex pathophysiology and alters different metabolic pathways. Excess inflammation, endothelial damage, and the use of angiotensin converting enzyme 2 (ACE-2) as crucial cellular entrance for the virus, consist fundamental mechanisms of SARS-CoV-2 action. The suppression of the pathways involved in lung tissue destruction by specialized micromolecular agents such as Rho kinase inhibitors, along with the efficiency of multiple micronutrients targeting these processes, may promisingly result in boosting the immune response against the viral agent (Abedi et al., 2020) .

Vit D has been proposed to have a special place on the cell protection mechanism by inhibiting the entrance of the virus in the cells via interaction of Vit D with its one receptor and ACE-2 (Glaab and Ostaszewski, 2020) . Also, Vit D enablement is crucial for immune function as it participates to the pathways of function for normal T-cells, macrophages, dendritic cells and other immune cells (Aranow, 2011; Sigmundsdottir et al., 2007) . Its role in the PLC-γ1 expression through a specific nuclear receptor is also mandatory for both the innate and adaptive immune systems (von Essen et al., 2010) . Most human studies on COVID-19 patients agree that Vit D within normal limits on admission may assist in a favorable outcome. This finding strengthens the hypotheses that Vit D acts both as an immune booster and an antiviral agent. The molecular mechanism that may explain the benefit of Vit D supplementation in COVID-19 patients is its immunomodulatory effect on interleukin-6 (IL-6) production. Vit D reduces immune cell IL-6 production, and potentially reduces pro-J o u r n a l P r e -p r o o f inflammatory effects, but it does not specifically target IL-6 receptors, avoiding any negative impact on IL-6 anti-inflammatory actions (Silberstein, 2020) . Furthermore, human studies have revealed a significant immunomodulatory capacity of Vit D to lower tumor necrosis factor (TNF) and interleukin-10 (IL-10) levels (Peterson and Heffernan, 2008; Schleithoff et al., 2006) . Thus, multiple pathways are probably activated by Vit D and result in favorable immunoregulation against COVID-19, as IL-6, IL-10 and TNF are primarily involved in excess inflammation in COVID-19 severe illness (Petersen and Ho, 2020). These findings, combined with the results of this systematic review, provide evidence for the use of Vit D as adjuvant factor targeting hyperinflammatory cytokines in COVID-19. Nevertheless, more clinical trials are needed to evaluate the action of Vit D supplements both in Vit D deficient patients and patients without insufficiency, along with its beneficial effects against the virus per se.

Calcium is along with Vit D the most studied molecule among critically ill COVID-19 patients. Hypocalcemia was a known abnormality accompanying multiple viral infections before the outbreak of COVID-19, thus low Ca levels among these patients were expected (Crespi and Alcock, 2021; Huang et al., 2020; Nathan et al., 2020) . Although the exact pathophysiological mechanism causing this abnormality has not been clarified yet and multiple hypotheses including malnutrition of the elderlies, disturbed albumin binding and parathyroid hormone secretion caused by COVID-19 as well as the role of unsaturated fat elevation, have been proposed (Cappellini et al., 2020; Crespi and Alcock, 2021; Huang et al., 2020; Nathan et al., 2020; Torres et al., 2021) . Two recent metanalyses studying hypocalcemia as a risk factor for critically illness and intubation, revealed that hypocalcemia was related to high D-dimer levels and thus a more inflammatory response to SARS-CoV-2 (Alemzadeh et al., 2021; Paliogiannis et al., 2020) . Vice versa, our results indicate that normal Ca levels act protectively as they are related to survival. It is important to underline that SARS-CoV-2 cellular hypoxia leads to alteration of Ca cell signaling and results in great increase of intracellular Ca through two different processes: i) hijacking the Ca channels and pumps, thus intracellular Ca cannot get out of the cell and ii) enhancing the cellular entry of J o u r n a l P r e -p r o o f extracellular Ca obligatory for the translation of HIF-1α and HIF-2α, a process stimulated by hypoxia (Danta, 2020; Danta, 2021; Gusarova et al., 2011; Hui et al., 2006; Serebrovska et al., 2020) . This pathophysiological process gives evidence that patients with normal serum Ca levels may not be attacked by SARS-CoV-2 in such a degree that cellular hypoxia has absorbed most of the extracellular Ca and that could explain why normocalcaemia on admission is related to survival. If this hypothesis works, Ca supplements cannot act as an adjuvant therapy targeting SARS-CoV-2 inflammatory cascade but only as a protective therapy to the crucial consequences of hypocalcemia itself.

Zinc belongs to minerals/metalloids and constitutes a co-factor for several enzymes participating in antioxidant reactions that assist the immune system (Black, 2003) . Zn deficiency disturbs the development of immune cells and thus cell-mediated immunity but also humeral immunity (Maares and Haase, 2016; Skalny et al., 2020; Tuerk and Fazel, 2009 ). In clinical practice Zn deficiency has been related both to viral infections and severe pneumonia among the elderly and has been effective as a nutrient supplement in the recovery from common cold (Barnettet et al., 2010; Mossad et al., 1996; Read et al., 2019) . Zn has been found to participate in the molecular pathways of acute respiratory syndrome, as animal studies have proved that Zn deficiency results in significant increase in proinflammatory molecules along with lung epithelium remodeling and thus in increased permeability of proinflammatory markers that lead the cell to apoptosis (Bao and Knoell, 2006; Biaggio et al., 2010; Liu et al., 2014; St Croix et al., 2005) . Zn deficiency may also participate in the inflammatory process that results in lung fibrosis (Biaggio et al., 2012) . As for COVID-19, the aforementioned mechanisms may explain the clinical improvement of patients with normal Zn levels compared to those with Zn deficiency while a reverse association between Zn and IL-6 levels as well as Zn capability to inhibit SARS-CoV-2 RNA polymerase are described (Domingo and Marquès, 2021) . In addition, in vitro experiments give indications that Zn may target and inhibit the SARS-CoV-2 agent itself (Iyigundogdu et al., 2017; Zhang and Liu, 2020) . If we further consider the fact that Zn has worked as an adjuvant therapy in acute respiratory syndrome along with the results of the present review, Zn appears to be a J o u r n a l P r e -p r o o f promising nutrient supplement as an adjuvant treatment for COVID-19 patients (Haider et al., 2011; Skalny et al., 2020) . Nevertheless, large scale clinical studies are needed to confirm this hypothesis.

This review indicates that other metalloids such as Se and Mg may relate to the prognosis of patients with SARS-CoV-2 infection. Mg is a crucial co-factor for multiple enzymatic reactions and low levels of Mg have been related to increased proinflammatory and inflammatory markers as well as molecules that disturb the normal endothelial function (Chacko et al., 2010) . Selenium has been discussed as a crucial biomarker for the prognosis of multiple viral infections including influenza, coxsackie virus, cytomegalovirus and hepatitis C. Abnormal low levels of this molecule have been related to high pathogenicity of influenza and suppressed immune response against the agent (Chacko et al., 2010; Harthill, 2011; Steinbrenner et al., 2015) . Domingo and Marquès reviewed the role of Se in regulating the host defense against SARS-CoV-2 and corroborate the immunomodulatory properties of this metalloid as well as the negative role of Se deficiency in COVID-19 patients (Domingo and Marquès, 2021) . Phosphate participates in cell and tissue regeneration. Thus, high P levels may assist the cellular effort to maintain alive during the infection. However, neither animal nor in vivo studies have clarified the exact pathways and findings from human studies remain weak (Kumar et al., 2021) . Other micronutrients that are discussed to act beneficially against SARS-CoV-2 but findings from human studies and clinical trials are not clear, are Vit C, Vit E, Fe, copper and other antioxidants (Cheng, 2020; Domingo and Marquès, 2021; Tavakol and Seifalian, 2021; Tojo et al., 2021) .

The COVID-19 pandemic is a major threat to human life all over the world. The absence of an effective anti-SARS-CoV-2 treatment trace each possible favorable adjuvant therapy vital for the survival of critical and non-critical ill patients. This systematic review highlights the importance of a healthy micronutrient status for a favorable outcome in COVID-19. Vit D, Ca J o u r n a l P r e -p r o o f and Zn may make a significant difference if used as nutritional supplements on a primary point, but further clinical trials need to confirm it. In addition, micronutrients' deficiency on admission seems to be related with high risk for ICU admission, intubation and even death.

Thus, it is important for individuals to maintain a healthy and balanced nutritional status to overcome a possible COVID-19 infection while further studies are required to evaluate if vitamin supplements would assist or not, a vaccinated or not individual, to actually contract SARS-CoV-2. 

Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19)

MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents

Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia

Mortality risk factors among hospitalized COVID-19 patients in a major referral center in Iran

The effect of low serum Ca level on the severity and mortality of Covid patients: A systematic review and meta-analysis

Malnutrition: percentage and association with prognosis in patients hospitalized for Coronavirus Disease

Predicting COVID-19 progression from diagnosis to recovery or death linking primary care and hospital records in Castilla y Leon (Spain)

Vitamin D and the immune system

Zinc modulates cytokine-induced lung epithelial cell barrier permeability

Low zinc status: a new risk factor for pneumonia in the elderly?

Vitamin D deficiency and low serum Ca as predictors of poor prognosis in patients with severe COVID-19

Alteration in the expression of inflammatory parameters as a result of oxidative stress produced by moderate zinc deficiency in rat lung

Alterations of the extracellular matrix of lung during zinc deficiency

The role of Zinc and Copper in insulin resistance and diabetes mellitus

Zinc deficiency, infectious disease and mortality in the developing world

Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital

Low levels of total and ionized Ca in blood of COVID-19 patients

Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women

Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19

Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19

Conflicts over Ca and the treatment of COVID-19

Ca Channel Blockers: A possible potential therapeutic strategy for the treatment of Alzheimer's dementia patients with SARS-CoV-2 infection

SARS-CoV-2, hypoxia, and Ca signaling: The consequences and therapeutic options

with COVID-19: a randomized clinical trial

The effects of some essential and toxic metals/metalloids in COVID-19: A review

Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study

The association between micronutrient and hemogram values and prognostic factors in COVID-19 patients: A single-center experience from Turkey

Selenium supplementation affects insulin resistance and serum hs-CRP in patients with type 2 diabetes and coronary heart disease

The Role of Spike-ACE2 Interaction in Pulmonary Blood Pressure Regulation

Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths

Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19)

Hypoxia leads to Na,K-ATPase downregulation via Ca(2+) release-activated Ca(2+) channels and AMPK activation

Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age

CD007368

Review: micronutrient S deficiency influences evolution of some viral infectious diseases

Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker

High levels of vitamin D associated with less ischemic heart disease -a nested case-control study among rural men in Sweden

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression

Ca signaling stimulates translation of HIF-alpha during hypoxia

Low vitamin D status at admission as a risk factor for poor survival

An Italian retrospective study

Developing Novel Antimicrobial and Antiviral Textile Products

Virology, epidemiology, pathogenesis, and control of COVID-19

Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors

Inhibition of SARS-CoV 3CL protease by flavonoids

COVID-19: Poor outcomes in patients with zinc deficiency

Impact of Serum 25(OH) Vitamin D level on mortality in patients with COVID-19 in Turkey

Clinical features and short-term outcomes of COVID-19 in Tehran, Iran: An analysis of mortality and hospital stay

Inactivation of Middle East respiratory syndrome coronavirus (MERS-CoV) in plasma products using a riboflavin-based and ultraviolet light-based photochemical treatment

Role of vitamins and minerals as immunity boosters in COVID-19

IHU COVID-19 Task force, 2020. Outcomes of 3,737 COVID-19 patients treated withhydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel medicine and infectious disease

Diet and the developing immune system

Effective inhibition of MERS-CoV infection by resveratrol

Prevalence and predictive value of hypocalcemia in severe COVID-19 patients

Zinc regulates the acute phase response and serum amyloid A production in response to sepsis through JAK-STAT3 signaling

Exploring the link between vitamin D and clinical outcomes in COVID-19

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Zinc and immunity: An essential interrelation

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse with COVID-19 infection

Changes in the immune system are conditioned by nutrition

Folate levels in patients hospitalized with Coronavirus Disease

Zinc gluconate lozenges for treating the common cold. A randomized, double-blind

Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial

Ca ions directly interact with the Ebola virus fusion peptide to promote structure-function changes that enhance infection

Factors associated with prompt recovery among hospitalised patients with J o u r n a l P r e -p r o o f coronavirus disease 2019

D-Dimer concentrations and COVID-19 severity: A systematic review and metaanalysis

SARS-CoV-2: a storm is raging

Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women

Vitamin D deficiency and outcome of COVID-19 patients

The Role of Zinc in Antiviral Immunity

Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients

Micronutrients and respiratory infections: the biological rationale and current state of clinical evaluation

Effects of micronutrients or conditional amino acids on COVID-19-related outcomes: An evidence analysis center scoping review

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition

ReCOV: recovery and rehabilitation during and after COVID-19 -a study protocol of a longitudinal observational study on patients, next of kin and health care staff. BMC sports science, medicine & rehabilitation

Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial

Hypoxia, HIF-1alpha, and COVID-19: from pathogenic factors to potential therapeutic targets

DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27

Correlation between premorbid IL-6 levels and COVID-19 mortality: Potential role for Vitamin D

Zinc and respiratory tract infections

Nitric oxide and zinc homeostasis in acute lung injury

Dietary S in adjuvant therapy of viral and bacterial infections

Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease

Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update

Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment

COVID-19 vaccines: Current evidence and considerations

Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality

Baseline electrolyte abnormalities would be related to poor prognosis in hospitalized coronavirus disease 2019 patients

Author Correction: The Ushaped association of serum iron level with disease severity in adult hospitalized patients with COVID19

Time to recovery from COVID-19 and its predictors among patients admitted to treatment center of Wollega University Referral Hospital (WURH), Western Ethiopia: Survival analysis of retrospective cohort study

COVID19 Hospital Clínic Infectious Diseases Research Group, 2021. Impact of low serum calcium at hospital admission on SARS-CoV-2 infection outcome

Zinc deficiency

Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. The American journal of emergency medicine

Low 25-Hydroxyvitamin D levels on admission to the intensive care unit may higher 28-day mortality risk: A pilot study on a Greek ICU cohort

Vitamin D controls T cell antigen receptor signaling and activation of human T cells

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Understanding the potential impact of different drug properties on SARS-CoV-2 transmission and disease burden: A modelling analysis

Coronavirus disease 2019 (COVID-19)

Coronavirus Disease (COVID-19) Dashboard

Risk factors associated with long-term hospitalization in patients with COVID-19: A single-centered, retrospective study

Low serum calcium and phosphorus and their clinical performance in detecting J o u r n a l P r e -p r o o f COVID-19 patients

Potential interventions for novel coronavirus in China: A systematic review

Risk factors related to the severity of COVID-19 in Wuhan

COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU

China Novel Coronavirus Investigating and Research Team, 2020. A novel coronavirus from patients with pneumonia in China